BioXcel Therapeutics, Inc. (BTAIQ)
OTCMKTS · Delayed Price · Currency is USD
0.044555
-0.016945 (-27.55%)
At close: Sep 22, 2026
BioXcel Therapeutics Revenue
BioXcel Therapeutics had revenue of $182.00K in the quarter ending June 30, 2026, with 51.67% growth. This brings the company's revenue in the last twelve months to $742.00K, down -14.52% year-over-year. In the year 2025, BioXcel Therapeutics had annual revenue of $642.00K, down -71.67%.
Revenue (ttm)
742.00K
Revenue Growth
-14.52%
P/S Ratio
1.88
Revenue / Employee
25.59K
Employees
29
Market Cap
1.39M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 642.00K | -1.62M | -71.67% |
| Dec 31, 2024 | 2.27M | 886.00K | 64.20% |
| Dec 31, 2023 | 1.38M | 1.01M | 268.00% |
| Dec 31, 2022 | 375.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Medical Marijuana | 58.98M |
| Trees | 14.50M |
| Tian'an Pharmaceutical | 10.65M |
| CordovaCann | 9.83M |
| Procyon | 4.98M |
| CannaPharmaRX | 1.70M |
| Nascent Pharma Holdings | 1.03M |
| Anything Technologies Media | 257.70K |
BioXcel Therapeutics News
- 25 days ago - BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals - GlobeNewsWire
- 26 days ago - Biopharma firm BioXcel Therapeutics files for bankruptcy in US - Reuters
- 3 months ago - BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting - GlobeNewsWire
- 4 months ago - BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 5 months ago - BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting - GlobeNewsWire
- 5 months ago - Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 5 months ago - BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions - GlobeNewsWire
- 5 months ago - BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting - GlobeNewsWire